🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Jeena Sikho Lifecare Limited JSLL NSEPHARMA

Healthcare · Medical Care Facilities · India
https://jeenasikho.com
Company Profile ↓
₹363.35
-32.56% 1Y
Mkt Cap₹4,516.47 Cr
P/E19.14
P/B10.25
Div. Yield1.08%
52W High₹836.82
52W Low₹363.35
Book Value₹37.57
EPS (TTM)₹18.98

Company Overview

Jeena Sikho Lifecare Limited trades in ayurvedic products in India and internationally. It operates through Ayurvedic products/medicine, Ayurvedic healthcare services, and others segments. The company offers ayurvedic products under the Shuddhi brand name. It also provides services, including in-patient, out-patient, 72 hours health camps, Panchakarma therapies, dietary support and nutrition guidance, home-based healthcare services, and healthcare support centre services. In addition, the company operates clinics under the Shuddhi Ayurveda, Shuddhi Clinics, Hospital & Institution of Integrated Medical Sciences, Shuddhi Wellness Clinics & Hospital, Shuddhi Ayurveda Panchakarma Hospital, and Shuddhi Panchakarma Day Care Clinic names. Jeena Sikho Lifecare Limited was founded in 2009 and is headquartered in Zirakpur, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 47.5%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 54.5%.

Consistent Profit Growth

Net profit has compounded at 87.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 57.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 19.1, below the sector median of 36.4.

Healthy Margins

Maintains a net profit margin of 27.8%.

Recent Developments

  • Mar 2026 Revenue of ₹801.36 Cr (+70.8% YoY); net profit ₹221.85 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +28.8%, earnings +28.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 57.8%, profit CAGR 87.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:57.81%
1 Year:28.80%

Compounded Profit Growth

5 Years:87.34%
1 Year:28.40%

Stock Price Performance

1 Year:-32.56%
6 Months:-46.35%
3 Months:-34.52%
1 Month:-28.49%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
₹363.35 ₹836.82
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)20.59 · Oversold
Price Performance
1M-28.49%
3M-34.52%
6M-46.35%
1Y-32.56%
Valuation vs Sector

P/E of 19.14 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 47.5%.
  • Healthy ROCE of 54.5%.
  • Excellent profit margin of 27.8%.
  • Compounding revenue at 57.8% over 5 years.
  • Profit CAGR of 87.3% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 56.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).
  • RSI at 21 suggests oversold conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
19.14
Industry PE
36.43
Forward P/E
10.15
PEG Ratio
-
Book Value
₹37.57
Price to Book
10.25
P/S
5.62
EV/EBITDA
12.71
Dividend Yield
1.08%

Growth (CAGR)

Revenue 5Y
57.81%
Profit 5Y
87.34%
Revenue (YoY)
28.80%
Earnings (YoY)
28.40%

Profitability & Returns

ROCE
54.50%
ROE
47.50%
ROA
32.90%
Profit Margin
27.78%
Op Margin
34.17%
Gross Margin
88.39%
EPS (Latest Qtr)
₹3.62
EPS (TTM)
₹18.98

Balance Sheet & Liquidity

Debt/Equity
0.27
Quick Ratio
3.05
Current Ratio
3.25
Debt
₹127.30 Cr
Total Assets
₹674.24 Cr
Current Assets
₹340.87 Cr
Working Capital
₹235.88 Cr

Ownership

Promoter Holding
72.50%
Chg in Prom Hold
0.05%
FII / Inst Holding
0.32%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
₹4,516.47 Cr
Total Revenue (TTM)
₹851.48 Cr
EBITDA
₹367.13 Cr
Free Cash Flow
₹219.45 Cr
Operating Cash Flow
₹253.75 Cr
Shares Outstanding
₹12.43 Cr
Gross Margin
88.39%
Payout Ratio
5.80%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 JSLL Jeena Sikho Lifecare Limited NSEPHARMA 363.35 19.14 ₹4,516.47 Cr 1.08% 54.50% 47.50% 57.81% 87.34%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 114.00 Cr-139.25 Cr174.29 Cr189.85 Cr221.68 Cr215.55 Cr
Cost of Revenue --16.71 Cr11.09 Cr24.09 Cr24.20 Cr24.91 Cr
Gross Profit --122.54 Cr163.19 Cr165.76 Cr197.48 Cr190.64 Cr
Operating Expenses 74.00 Cr-85.80 Cr94.09 Cr84.13 Cr108.02 Cr129.11 Cr
Operating Income 34.00 Cr-36.74 Cr69.10 Cr81.63 Cr89.46 Cr61.54 Cr
EBITDA 40.00 Cr-46.04 Cr79.82 Cr93.47 Cr103.29 Cr81.34 Cr
Interest Expense 2.00 Cr-3.10 Cr1.66 Cr4.35 Cr3.10 Cr3.73 Cr
Pretax Income 35.00 Cr-33.91 Cr68.51 Cr78.73 Cr88.93 Cr61.23 Cr
Tax Provision 8.75 Cr-8.58 Cr17.24 Cr19.98 Cr22.33 Cr16.15 Cr
Net Income 27.00 Cr-25.34 Cr51.27 Cr58.75 Cr66.66 Cr45.13 Cr
Diluted EPS 2.14-2.044.124.725.353.62

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -203.90 Cr324.41 Cr469.07 Cr801.36 Cr
Cost of Revenue -21.77 Cr31.24 Cr54.22 Cr91.53 Cr
Gross Profit -182.13 Cr293.17 Cr414.85 Cr709.83 Cr
Operating Expenses -135.89 Cr205.26 Cr303.35 Cr408.10 Cr
Operating Income -46.24 Cr87.91 Cr111.50 Cr301.73 Cr
EBITDA -48.20 Cr99.09 Cr147.34 Cr357.92 Cr
Interest Expense -54.69 L7.10 L10.65 Cr12.83 Cr
Pretax Income -44.53 Cr93.92 Cr107.58 Cr297.39 Cr
Tax Provision -10.79 Cr24.71 Cr27.63 Cr75.70 Cr
Net Income -33.74 Cr69.21 Cr79.94 Cr221.85 Cr
Diluted EPS -2.745.576.4217.81

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -151.03 Cr220.53 Cr328.31 Cr674.24 Cr
Current Assets -77.48 Cr144.34 Cr152.16 Cr340.87 Cr
Cash & Equivalents -31.62 Cr59.86 Cr24.45 Cr16.37 Cr
Inventory -4.10 Cr7.19 Cr11.55 Cr20.22 Cr
Receivables -22.07 Cr41.19 Cr97.63 Cr69.93 Cr
Total Liabilities -25.23 Cr28.28 Cr55.29 Cr207.29 Cr
Current Liabilities -24.60 Cr27.41 Cr52.27 Cr104.98 Cr
Long Term Debt -53.95 L32.16 L42.92 L26.50 L
Total Debt -80.80 L53.95 L10.73 Cr127.30 Cr
Total Equity -125.80 Cr192.25 Cr273.02 Cr467.08 Cr
Shares Outstanding -12.43 Cr12.43 Cr12.43 Cr12.43 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -17.17 Cr36.69 Cr84.50 Cr253.75 Cr
Investing Cash Flow --57.23 Cr-18.05 Cr-64.48 Cr-201.68 Cr
Financing Cash Flow -48.00 Cr-3.44 Cr-22.45 Cr-58.68 Cr
Capital Expenditure --38.20 Cr-15.54 Cr-42.33 Cr-34.30 Cr
Free Cash Flow --21.03 Cr21.15 Cr42.17 Cr219.45 Cr
Net Change in Cash -7.94 Cr15.20 Cr-2.43 Cr-6.61 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -89.3%90.4%88.4%88.6%
Operating Margin % -22.7%27.1%23.8%37.7%
Net Margin % -16.5%21.3%17.0%27.7%
ROE % -26.8%36.0%29.3%47.5%
ROCE % -36.6%45.5%40.4%53.0%

Shareholding Pattern

Insiders
72.50%
Institutions
0.32%
Public Float
1.16%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JSLL

Google News ue, 11 Aug 2026

Is It Too Late To Consider Buying Jeena Sikho Lifecare Limited (NSE:JSLL)? - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPU285d0h1LXdqbm4xcVdUS1QyNWh2NjZNdXRocWFEd0hzNUJPd0x0eWFxUHZPT2FkbEN4WTY0TVJ2c1czWGxZLVZaWXJmcmljeFhEcEc4VEdDY1FYaDZ2OFFvR0hKOVdRV0JaSjctZjJmVkJ4WlZLZkgzaFppQlpXa0RPVkIzV0k1cFBBT0…

Google News ue, 20 Oct 2026

JSLL Q2 2026 Earnings: Revenue Jumps 70.36% to ₹799.10 Crore Even as Shares Slip 4.78% - ROA Comparison - https://www.siam.in/

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOYzZMUVlZaWpVRklldExJMGNycmRtcnU2ZFFpRmNTUDZ4UDM3dnBiU3lQZGFTbEJUc0JfRmFLUjUtTVBZdHRsYWwyeUNQTlVZRGxSMDF0NXJFbFJwUnludGpTNzhJUXIwYW1aS2hzNDlwMDlJcnFGZkZtSHB0SmkzMlFtY01QZVNGM0djUE…

Google News Wed, 03 Jun 2026

Choice reiterates 'Buy' on Jeena Sikho, sees 44% upside; stock rises 20% - Business Standard

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNN3dMX2RiaWJvOUE4X1R0emdmVkkxRE9xcmpRaTBhRnJtcEZnbXJ5eWdZVlRDRWE5cmtiSlNCOUZXWnJ5OV9YdjdidmtlVWpvRDZ4Q1YzR05MM0xoMVMzYVJMREZxdnNfYW5PcnlZVFlLeDZSd0FIRmQ5NFktdmtlMnNHaFJDdi14bGFPQU…

Google News Mon, 28 Sep 2026

Jeena Sikho Lifecare (NSEI:JSLL) Stock Forecast & Analyst Predictions - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPakw5Wk9iVXBxMTl1UGRtQmt2VlZZb1dsWnhYWi0tbXNsSEhvMEVMdWtjVHRBWlFibW1qRnJGQWhkN0xma1ZYU0p4aGY3QThtdHBGM3RqVmpFZUdWamd4MkNfUnNha2QxejNSckVXVFBKbFhOVTljSHdTM1RpQmJUNV8yaE1ZelZDbmx5LU…

Google News hu, 01 Oct 2026

JSLL Share Price Falls 5.06% Amid Trading Valuation - Univest

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxObmxPanA3QlNfankzcUQ0c2ltZldWUlJRa0hoMGlTTUIxUTlvN0U1U3QtSUJkMEliRmQzNjVTeVVuaVlXRTFBTG96SUR3YnF4a1BVNjNwdTlqSkFBQ0FjOWdWdUhWdm9RemR1dkcwOUNTWFBXYV9fSEtPcGFQQjF4YWpmbw?oc=5" targe…

Google News ue, 29 Sep 2026

Jeena Sikho Lifecare JSLL Promoter Share Purchase September 2026 - Kalkine India

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNd3NJdm1ZVmF2TTZHdm9fMnZEVUZoWm9QTV8wQ0FSODY4aWxMeTlnVEtoS1NXLWFhdGg3SXZ6VkVrckJWQUFqUFVjM1N3R3VCNDZNZ2c1VlRWMmtZUThxSzMzeTRlNVM3VHFrSXZaN1Y1YjEwclZZMkJSN2FtemU4b3Q1dkRscUVvdkdwbE…

JSLL — Frequently Asked Questions

What is the current share price of Jeena Sikho Lifecare Limited (JSLL)?

As of 2026-10-23 04:58 IST, Jeena Sikho Lifecare Limited (JSLL) trades at ₹363.35 on NSE. Its 52-week range is ₹363.35 to ₹836.82.

What is the market capitalisation of JSLL?

Jeena Sikho Lifecare Limited (JSLL) has a market capitalisation of ₹4,516.47 Cr on NSE.

What is the P/E ratio of JSLL?

JSLL trades at a trailing price-to-earnings (P/E) ratio of 19.14. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 10.25.

Does JSLL pay a dividend?

Jeena Sikho Lifecare Limited (JSLL) currently offers a dividend yield of 1.08%.

What is the return on equity (ROE) of JSLL?

JSLL has a return on equity (ROE) of 47.50%. Its return on capital employed (ROCE) is 54.50%.

Is JSLL a good stock to buy?

This page provides a data-driven analysis of Jeena Sikho Lifecare Limited (JSLL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space